Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FHNT5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,434
Award facts
- Contract value 100% obligated
- $16,433.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,433.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. The delivery order, issued on January 5, 2026, with an ultimate completion date of January 27, 2026, was awarded without a set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. This award represents a single transaction under the company's existing Indefinite Delivery Contract with DLA.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated SPE2DR, which was established under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative on November 13, 2025. The parent contract carries a $499.999 billion ceiling value with an ultimate completion date of December 31, 2036, and authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare facilities worldwide. EXPAREL is a specialty surgical anesthetic product that aligns with DMS Pharmaceutical Group's established portfolio of high-value specialty pharmaceuticals supplied to military medical operations.
Quick answers
Who was awarded contract SPE2DR26FHNT5?
SPE2DR26FHNT5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FHNT5 worth?
The government has obligated $16,434 on SPE2DR26FHNT5.
Is contract SPE2DR26FHNT5 an order under another contract?
Yes. SPE2DR26FHNT5 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNT5 competed?
The extent of competition for SPE2DR26FHNT5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award